Victoria Niklas
Director/Miembro de la Junta en FIBROBIOLOGICS, INC. .
Fortuna: 87 600 $ al 30/04/2024
Perfil
Victoria Niklas is an Independent Director at FibroBiologics, Inc. and the Chief Medical Officer at Oak Hill Bio Corp.
She was previously the Chief Medical & Scientific Officer at Prolacta Bioscience, Inc., Head-Neonatology at UCLA Health Systems, and Chief Division-Newborn Medicine at Nemours Children's Clinic, Inc. She holds a graduate degree from Harvard University, an undergraduate degree from Goucher College, and a doctorate from Harvard Medical School.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
FIBROBIOLOGICS, INC.
0.02% | 24/01/2024 | 7 500 ( 0.02% ) | 87 600 $ | 30/04/2024 |
Cargos activos de Victoria Niklas
| Empresas | Cargo | Inicio |
|---|---|---|
| FIBROBIOLOGICS, INC. | Director/Miembro de la Junta | 08/04/2021 |
Oak Hill Bio Corp.
 Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Director Técnico/Científico/I+D | 01/01/2022 |
Antiguos cargos conocidos de Victoria Niklas.
| Empresas | Cargo | Fin |
|---|---|---|
Prolacta Bioscience, Inc.
 Prolacta Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA. | Director Técnico/Científico/I+D | 01/01/2019 |
UCLA Health Systems
 UCLA Health Systems Hospital/Nursing ManagementHealth Services UCLA Health Systems operates hospitals. The private company is based in Los Angeles, CA and has subsidiaries in United States. The company was founded in 1955 by Benjamin J. Ansell. John Mazziotta has been the CEO of the company since 2015. | Corporate Officer/Principal | 01/01/2016 |
| Nemours Children's Clinic, Inc. | Corporate Officer/Principal | 01/01/2014 |
Formación de Victoria Niklas.
| Harvard University | Graduate Degree |
| Goucher College | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FIBROBIOLOGICS, INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Prolacta Bioscience, Inc.
Prolacta Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA. | Health Technology |
UCLA Health Systems
UCLA Health Systems Hospital/Nursing ManagementHealth Services UCLA Health Systems operates hospitals. The private company is based in Los Angeles, CA and has subsidiaries in United States. The company was founded in 1955 by Benjamin J. Ansell. John Mazziotta has been the CEO of the company since 2015. | Health Services |
| Nemours Children's Clinic, Inc. | |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Commercial Services |
- Bolsa de valores
- Insiders
- Victoria Niklas
